small molecule

ACZONE

DAPSONE

Loss of exclusivityNovember 2033latest FDA-listed patent expiry
CompanyAlmirallView the full company profile on CliffBio

Drug detail

Brand nameACZONE
Active ingredientDAPSONE
Strength7.5%
Dosage formGEL
RouteTOPICAL
ModalitySmall molecule
FDA approvalFebruary 2016
Marketing statusRX

Listed patents

PatentExpiresType
11273132November 2033product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ACZONE patent cliff — loss of exclusivity November 2033 | CliffBio